Rhein reverses the diabetic phenotype of mesangial cells over-expressing the glucose transporter (GLUT1) by inhibiting the hexosamine pathway

British Journal of Pharmacology

Volumn 153, Issue 7, 2008, Pages 1456-1464

  Zheng, J M ^a   Zhu, J M ^a   Li, L S ^a   Liu, Z H ^a,b  

^a MEDICAL SCHOOL OF NANJING UNIVERSITY   (China)

^b JINLING HOSPITAL   (China)

Author keywords

Anthraquinone compound; Diabetic nephrology; GLUT1; Hexosamine pathway; Mesangial cells; Rhein

Indexed keywords

BCR ABL PROTEIN; BETA ACTIN; FIBRONECTIN; GLUCOSE TRANSPORTER 1; GLUTAMINE FRUCTOSE 6 PHOSPHATE AMINOTRANSFERASE; HEXOSAMINE; MESSENGER RNA; PROTEIN P21; RHEIN; TRANSFORMING GROWTH FACTOR BETA1; URIDINE DIPHOSPHATE N ACETYLGLUCOSAMINE;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DRUG INHIBITION; ENZYME ACTIVITY; GLUCOSE TRANSPORT; HYPERTROPHY; IN VITRO STUDY; MALE; MESANGIUM CELL; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; RAT;

ANIMALS; ANTHRAQUINONES; CELLS, CULTURED; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DIABETIC NEPHROPATHIES; ENZYME INHIBITORS; EXTRACELLULAR MATRIX; GENE EXPRESSION REGULATION; GLUCOSE TRANSPORTER TYPE 1; HEXOSAMINES; HYPERTROPHY; MALE; MESANGIAL CELLS; PHENOTYPE; RATS; RATS, SPRAGUE-DAWLEY; TRANSFORMING GROWTH FACTOR BETA1;

EID: 41649096963     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1038/bjp.2008.26     Document Type: Article

References (44)

1. Ayo SH, Radnik RA, Glass 2nd WF, Garoni JA, Rampt ER, Appling DR (1991). Increased extracellular matrix synthesis and mRNA in mesangial cells grown in high-glucose medium. Am J Physiol 260: F185-F191.
2. Beccerica E, Ferretti G, Curatola G, Cervini C (1990). Diacetylrhein and rhein: in vivo and in vitro effect on lymphocyte membrane fluidity. Pharmacol Res 22: 277-285.
3. Browniee M (2001). Biochemistry and molecular cell biology of diabetic complications. Nature 414: 813-820.
4. Caldon CE, Daly RJ, Sutherland RL, Musgrove EA (2006). Cell cycle control in breast cancer cells. J Cell Biochem 97: 261-274.
5. Castiglione S, Fanciulli M, Bruno T, Evangelista M, Del Carlo C, Paggi MG et al. (1993). Rhein inhibits glucose uptake in Ehrlich ascites tumor cells by alteration of membrane-associated functions. Anticancer Drugs 4: 407-414.
6. Chang Q, Su K, Baker JR, Yang X, Paterson AJ, Kudlow JE (2000). Phosphorylation of human glutamine:fructose-6-phosphate amidotransferase by cAMP-dependent protein kinase at serine 205 blocks the enzyme activity. J Biol Chem 275: 21981-21987.
7. Crook ED, Simmons ST, Daniels M, Singh LP (2000). Regulation of glutamine:fructose-6-phosphate amidotransferase activity by high glucose and transforming growth factor beta in rat mesangial cells. J Investig Med 48: 427-434.
8. Hawkins M, Barzilai N, Liu R, Hu M, Chen W, Rosetti L (1997). Role of the glucosamine pathway in fat-induced insulin resistance. J Clin Invest 99: 2173-2182.
9. Hebert Jr LF, Daniels MC, Zhou J, Crook ED, Turner RL, Simmons ST (1996). Overexpression of glutamine: fructose-6-phosphate amidotransferase in transgenic mice leads to insulin resistance. J Clin Invest 98: 930-936.
10. Heilig CW, Concepcion LA, Riser BL, Freytag SO, Zhu M, Cortes P (1995). Overexpression of glucose transporters in rat mesangial cells cultrued in a normal glucose medium mimics the diabetic phenotype. J Clin Invest 96: 1802-1814.
11. Heilig CW, Liu Y, England RL, Freytag SO, Gilbert JD, Heilig Ko (1997). -glucose stimulates mesangial cell GLUT1 expression and basal IGF-I-sensitive glucose uptake in rat mesangial cells: implications for diabetic nephropathy. Diabetes 46: 1030-1039.
12. Huang Y, Wongamorntham S, Kasting J, McQuillan D, Owens RT, Yu L et al. (2006). Renin increases mesangial cell transforming growth factor-beta1 and matrix proteins through receptor-mediated, angiotensin II-independent mechanisms. Kidney Int 69: 105-113.
13. Inoki K, Haneda M, Maeda S, Koya D, Kikkawa R (1999). TGF-beta 1 stimulates glucose uptake by enhancing GLUT1 expression in mesangial cells. Kidney Int 55: 1704-1712.
14. James LR, Ingram A, Ly H, Thai K, Cai L, Scholey JW (2001). Angiotensin II activates the GFAT promoter in mesangial cells. Am J Physiol Renal Physiol 281: F151-F162.
15. Jia ZH, Liu ZH, Zheng JM, Zeng CH, Li LS (2007). Combined therapy of rhein and benazepril on the treatment of diabetic nephropathy in db/db mice. Exp Clin Endocrinol Diabetes 115: 571-576.
16. Kolm-Litty V, Sauer U, Nerlich A, Lehmann R, Schleicher ED (1998). High glucose-induced transforming growth factor beta1 production is mediated by the hexosamine pathway in porcine glomerular mesangial cells. J Clin Invest 101: 160-169.
17. Kreisberg JI, Karnovsky MJ (1983). Glomerular cells in culture. Kidney Int 23: 439-447.
18. Liu ZH, Li LS, Hu WX, Zhou H (1996). Effect of emodin on c-myc proto-oncogen expression in cultured rat mesangial cells. Acta Pharmacol Sin 17: 61-63.
19. Locatelli F, Canaud B, Eckardt KU, Stenvinkel P, Wanner C, Zoccali C (2003). The importance of diabetic nephropathy in current nephrological practice. Nephrol Dial Transplant 18: 1716-1725.
20. Manzari B, Kudlow JE, Fardin P, Merello E, Ottaviano C, Puppo M et al. (2007). Induction of macrophage glutamine: fructose-6-phosphate amidotransferase expression by hypoxia and by picolinic acid. Int J Immunopathol Pharmacol 20: 47-58.
21. Marshall S, Bacote V, Traxinger RR (1991). Discovery of a metabolic pathway mediating glucose-induced desensitization of the glucose transport system: role of hexosamine biosynthesis in the induction of insulin resistance. J Biol Chem 266: 4706-4712.
22. Masson E, Wiernsperger N, Lagarde M, El Bawab S (2005). Glucosamine induces cell-cycle arrest and hypertrophy of mesangial cells: implication of gangliosides. Biochem J 388 (Part 2): 537-544.
23. Masson E, Lagarde M, Wiernsperger N, El Bawab S (2006). Hyperglycemia and glucosamine-induced mesangial cell cycle arrest and hypertrophy: common or independent mechanisms? IUBMB Life 58: 381-388.
24. Mauer SM, Steffes MW, Ellis EN, Sutherland DE, Brown DM, Goetz FC (1984). Structural-functional relationships in diabetic nephropathy. J Clin Invest 74: 1143-1155.
25. McClain DA, Crook ED (1996). Hexosamines and insulin resistance. Diabetes 45: 1003-1009.
26. Miccadei S, Pulselli R, Floridi A (1993). Effect of lonidamine and rhein on the phosphorylation potential generated by respiring rat liver mitochondria. Anticancer Res 13: 1507-1510.
27. Molitch ME (1997). The relationship between glucose control and the development of diabetic nephropathy in type I diabetes. Semin Nephrol 17: 101-113.
28. Obici S, Wang J, Chowdury R, Feng Z, Siddhanta U, Morgan K (2002). Identification of a biochemical link between energy intake and energy expenditure. J Clin Invest 109: 1599-1605.
29. Oh JH, Ha H, Yu MR, Lee HB (1998). Sequential effects of high glucose on mesangial cell transforming growth factor-beta 1 and fibronectin synthesis. Kidney Int 54: 1872-1878.
30. Paterson AJ, Kudlow JE (1995). Regulation of glutamine:fructose-6- phosphate amidotransferase gene transcription by epidermal growth factor and glucose. Endocrinology 136: 2809-2816.
31. Patti ME, Virkamaki A, Landaker EJ, Kahn CR, Yki-Jarvinen H (1999). Activation of the hexosamine pathway by glucosamine in vivo induces insulin resistance of early post-receptor insulin signaling events in skeletal muscle. Diabetes 48: 1562-1571.
32. Phillips CA, Molitch ME (2002). The relationship between glucose control and the development and progression of diabetic nephropathy. Curr Diab Rep 2: 523-529.
33. Simmons ST, Daniels MC, Huddleston E, Hebert Jr LF, McClain DA, Crook ED (1999). Insulin stimulation of glutamine: fructose-6-phosphate amidotransferase occurs via an insulin-like growth factor-1 pathway in rat fibroblasts. Res Commun Mol Pathol Pharmacol 104: 63-72.
34. Stull MA, Rowzee AM, Loladze AV, Wood TL (2004). Growth factor regulation of cell cycle progression in mammary epithelial cells. J Mammary Gland Biol Neoplasia 9: 15-26.
35. Tang J, Neidigh JL, Cooksey RC, McClain DA (2000). Transgenic mice with increased hexosamine flux specifically targeted to beta-cells exhibit hyperinsulinemia and peripheral insulin resistance. Diabetes 49: 1492-1499.
36. Traxinger RR, Marshall S (1991). Coordinated regulation of glutamine: fructose-6-phosphate amidotransferase activity by insulin, glucose, and glutamine: role of hexosamine biosynthesis in enzyme regulation. J Biol Chem 266: 10148-10154.
37. van Det NF, van den Born J, Tamsma JT, Verhagen NA, Berden JH, Bruijn JA (1996). Effects of high glucose on the production of heparan sulfate proteoglycan by mesangial and epithelial cells. Kidney Int 49: 1079-1089.
38. Wahab NA, Harper K, Mason RM (1996). Expression of extracellular matrix molecules in human mesangial cells in response to prolonged hyperglycaemia. Biochem J 316 (Part 3): 985-992.
39. Wardle EN (1994). Vascular permeability in diabetics and implications for therapy. Diabetes Res Clin Pract 23: 135-139.
40. Wolf G, Sharma K, Chen Y, Ericksen M, Ziyadeh FN (1992). High glucose-induced proliferation in mesangial cells is reversed by autocrine TGF-beta. Kidney Int 42: 647-656.
41. Wolf G (2000). Cell cycle regulation in diabetic nephropathy. Kidney Int Suppl 77: S59-S66.
42. Ye F, Maegawa H, Morino K, Kashiwagi A, Kikkawa R, Xie M et al. (2004). A simple and sensitive method for glutamine: fructose-6-phosphate amidotransferase assay. J Biochem Biophys Methods 59: 201-208.
43. Yu L, Border WA, Anderson I, McCourt M, Huang Y, Noble NA (2004). Combining TGF-b inhibition and angiotensin II blockade results in enhanced anti-fibrotic effect. Kidney Int 66: 1774-1784.
44. Zheng F, Fornoni A, Elliot SJ, Guan Y, Breyer MD, Striker LJ et al. (2002). Upregulation of type I collagen by TGF-beta in mesangial cells is blocked by PPARgamma activation. Am J Physiol Renal Physiol 282: F639-F648.